Mirum Pharamceuticals (MIRM) PT Raised to $39 at Baird

Baird analyst Brian Skorney raised the price target on Mirum Pharamceuticals (NASDAQ: MIRM) to $39.00 (from $34.00) while maintaining a Outperform rating.

The analyst commented: "Raising target price on positive volixibat results. Volixibat demonstrated unprecedented reductions in pruritis in the Phase 2 VANTAGE study in PBC, opening the door for a competitive profile in PBC and a clear road to approval in PSC. We believe these results are better than expected, with the itch reductions surpassing what has been seen from seladelpar. As a result we are increasing our probability of success for volixibat across these two indications and raising our target price to $39."

You May Also Be Interested In

• Constellation Brands (STZ) PT Lowered to $145 at UBS on Softer Consumer Backdrop
• AutoZone (AZO) PT Lowered to $4,230 at UBS Following 'Underwhelming' Q4 Print
• Viking Therapeutic (VKTX) PT Raised to $87 at Truist Securities